DYADIC INTERNATIONAL INC Payments of Stock Issuance Costs
DYADIC INTERNATIONAL INC (DYAI) reported Payments of Stock Issuance Costs of $808.71 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-03-25
- DYADIC INTERNATIONAL INC payments of stock issuance costs for the quarter ending 2025-12-31 was -$55.00.
- DYADIC INTERNATIONAL INC payments of stock issuance costs for the quarter ending 2025-09-30 was $808.76K.
- DYADIC INTERNATIONAL INC payments of stock issuance costs for fiscal 2025 was $808.71K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$55.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $808.71K derived: sum of 2 quarters · filed 2026-03-25 | $808.71K 10-K · filed 2026-03-25 | |
| 2025-09-30 | $808.76K 10-Q · filed 2025-11-12 | $808.76K 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |